Marty Freed

Marty Freed co-founded Civitas Therapeutics, Inc. and served as its Chief Medical Officer for four years. After Acorda Therapeutics acquired the company, he served as Senior Vice President, Clinical Development. In addition, he was Chief Medical Officer for Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb) and Vitae Pharmaceuticals, Inc. He also was a consultant working as an acting Chief Medical Officer for Avila Therapeutics, Inc. and Taligen Therapeutics. Across these roles, he provided strategic, operational, and medical leadership for clinical pharmacology, development strategy, and preclinical development. Marty spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals, where he served in numerous roles, including vice president, clinical development and medical affairs in the metabolism therapeutic area. He has authored more than 100 publications and presentations. He was a post-doctoral Fellow in Nephrology at Yale-New Haven Hospital and completed his Residency in General Internal Medicine from Temple University Hospital. He received his PhD from Pennsylvania State University College of Medicine and BA with Distinction, Biology from the University of Delaware.